Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 442Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 133Stomach Neoplasms 117Neoplasm Metastasis 97Neoplasms 64Esophageal Neoplasms 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Lymphoma 49Leukemia 41Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Burkitt Lymphoma 33Adenocarcinoma 29Cholangiocarcinoma 27Biliary Tract Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Lymphoma, Non-Hodgkin 19Esophageal Squamous Cell Carcinoma 15Osteosarcoma 14Liver Neoplasms 14Bile Duct Neoplasms 14Unspecified Adult Solid Tumor, Protocol Specific 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Biphenotypic, Acute 13Ovarian Neoplasms 12Leukemia, Myeloid, Acute 12

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡